Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
We are committed to increasing access to stem cell transplant procedures, making it safer and more effective for patients, reducing transplant-related complications and improving immune system recovery.
stem cell transplant clinical trials are nationally recognized for major advances in cancer treatment as a result of our research, including:
We're also home to the
Connell and O'Reilly Families Cell Manipulation Core Facility, which is New England's only state-of-the-art cell manipulation facility. This facility processes hematopoietic stem cells for transplant, generate modified tumor cells as therapeutic vaccines, and prepare immune cell populations for adoptive therapy.
Learn about current stem cell transplant clinical trials at Dana-Farber/Brigham and Women's Cancer Center
Appointments and Second Opinions
David Weinstock, MD, discusses his work with stem cell transplant patients, and describes how Dana-Farber rapidly translates laboratory discoveries to patient treatments